Candel Therapeutics (CADL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.36
- Estimate
- -$0.23
- Surprise
- -52.9%
- Score today
- 4.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Candel Therapeutics (CADL) reported a wider loss than forecast — adjusted EPS of -$0.36 against the -$0.23 estimate (a 52.9% shortfall).
Coverage in the report window
- B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12 — benzinga, 2026-08-14
- HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target — benzinga, 2026-08-13
- Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates CADL Sell at 4.4/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -52.9% surprise compares with a +15.2% four-quarter average. Next scheduled report: 2027-03-11.
What argues against it
- Concentration risk — Pipeline: aglatimagene
- DATA_ISSUE: analyst_target_implausible (raw $17.67 vs price $5.81 — ratio 3.0×). Rejected, falling back to technical TP.
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $5.81
- Price target
- $9.64
- Stop
- $5.40
- Upside to target
- +65.9%
Risk check: trading volume is running 2.1× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
CADL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $486.4M
- P/E (fwd)
- -4.3
- 52-week range
- $4.35–$14.00
- Off 52-week high
- 58.5%
- RSI (14)
- 35
- Volume vs avg
- 2.15×
- Score today
- 4.4/10